Literature DB >> 16723537

Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission.

Maria R Domenici1, Shahnaz C Azad, Giovanni Marsicano, Anja Schierloh, Carsten T Wotjak, Hans-Ulrich Dodt, Walter Zieglgänsberger, Beat Lutz, Gerhard Rammes.   

Abstract

It is widely accepted that cannabinoids regulate GABA release by activation of cannabinoid receptor type 1 (CB1). Results obtained from a variety of brain regions consistently indicate that cannabinoid agonists can also reduce glutamatergic synaptic transmission. However, there are still conflicting data concerning the role of CB1 in cannabinoid-induced inhibition of glutamatergic transmission in cortical areas. Here, we provide direct evidence that activation of CB1 on terminals of principal neurons controls excitatory synaptic responses in the forebrain. In slices of the basolateral amygdala, the CA1 region of the hippocampus, and the primary somatosensory cortex of wild-type mice, application of the CB1 agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone (WIN55,212-2; WIN) (5 mum) reduced evoked excitatory postsynaptic responses. In contrast, in slices obtained from conditional mouse mutants lacking CB1 in all principal forebrain neurons but not in GABAergic interneurons (CB1(f/f;CaMKIIalphaCre)), WIN no longer affected glutamatergic synaptic transmission in any of the brain regions tested. Compatible with a presynaptic mechanism, WIN did not change the sensitivity to focally uncaged l-glutamate. WIN reduced glutamatergic responses in slices obtained from mice lacking CB1 exclusively in GABAergic neurons (CB1(f/f;Dlx5/6-Cre)), thus excluding the involvement of CB1 expressed on GABAergic neurons in this effect of the drug. The present data strongly indicate that excitatory synaptic transmission in forebrain areas is directly modulated by CB1 expressed on presynaptic axon terminals originating from glutamatergic neurons.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16723537      PMCID: PMC6675276          DOI: 10.1523/JNEUROSCI.0372-06.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  80 in total

1.  Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure.

Authors:  M N Hill; S A Kumar; S B Filipski; M Iverson; K L Stuhr; J M Keith; B F Cravatt; C J Hillard; S Chattarji; B S McEwen
Journal:  Mol Psychiatry       Date:  2012-07-10       Impact factor: 15.992

2.  Suppression of CpG-ODN-mediated IFNα and TNFα response in human plasmacytoid dendritic cells (pDC) by cannabinoid receptor 2 (CB2)-specific agonists.

Authors:  Joseph E Henriquez; Robert B Crawford; Norbert E Kaminski
Journal:  Toxicol Appl Pharmacol       Date:  2019-02-23       Impact factor: 4.219

Review 3.  Endocannabinoids in the dentate gyrus.

Authors:  Charles J Frazier
Journal:  Prog Brain Res       Date:  2007       Impact factor: 2.453

Review 4.  Functional Relevance of Endocannabinoid-Dependent Synaptic Plasticity in the Central Nervous System.

Authors:  Shana M Augustin; David M Lovinger
Journal:  ACS Chem Neurosci       Date:  2018-02-19       Impact factor: 4.418

Review 5.  Seeing through the smoke: Human and animal studies of cannabis use and endocannabinoid signalling in corticolimbic networks.

Authors:  Mason M Silveira; Jonathon C Arnold; Steven R Laviolette; Cecilia J Hillard; Marta Celorrio; María S Aymerich; Wendy K Adams
Journal:  Neurosci Biobehav Rev       Date:  2016-09-14       Impact factor: 8.989

Review 6.  Amygdala FAAH and anandamide: mediating protection and recovery from stress.

Authors:  Ozge Gunduz-Cinar; Matthew N Hill; Bruce S McEwen; Andrew Holmes
Journal:  Trends Pharmacol Sci       Date:  2013-10-25       Impact factor: 14.819

7.  Endocannabinoid signaling controls pyramidal cell specification and long-range axon patterning.

Authors:  Jan Mulder; Tania Aguado; Erik Keimpema; Klaudia Barabás; Carlos J Ballester Rosado; Laurent Nguyen; Krisztina Monory; Giovanni Marsicano; Vincenzo Di Marzo; Yasmin L Hurd; Francois Guillemot; Ken Mackie; Beat Lutz; Manuel Guzmán; Hui-Chen Lu; Ismael Galve-Roperh; Tibor Harkany
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-18       Impact factor: 11.205

Review 8.  Cannabis and psychosis/schizophrenia: human studies.

Authors:  Deepak Cyril D'Souza; Richard Andrew Sewell; Mohini Ranganathan
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-16       Impact factor: 5.270

Review 9.  Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate.

Authors:  K Rea; M Roche; D P Finn
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

10.  Delta FosB and AP-1-mediated transcription modulate cannabinoid CB₁ receptor signaling and desensitization in striatal and limbic brain regions.

Authors:  Matthew F Lazenka; Bethany G David; Aron H Lichtman; Eric J Nestler; Dana E Selley; Laura J Sim-Selley
Journal:  Biochem Pharmacol       Date:  2014-08-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.